“Quo Vadis” Oncologic Hyperthermia?

Szász, András

doi:10.1155/2013/201671

Cited by 4 publications

(6 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This dose and the complete control are debated and cause the rare acceptance of hyperthermia in oncology. The actually applied doses are unsatisfactory [4] [6] [7], and due to the applied technologies it could not be significantly improved [8]. Oncothermia offers a new paradigm with nanoscopic heating to surmount this present complex problem.…”

Section: Dosing Methodsmentioning

confidence: 99%

Heating, Efficacy and Dose of Local Hyperthermia

Szász¹,

Szász²

2016

OJBIPHY

Self Cite

View full text Add to dashboard Cite

Hyperthermia in oncology needs a definite dose which fixes well the clinical protocols. The temperature is far not a dose, it is mass independent. The half of the mass has the same temperature in equilibrium, so the basic criteria of the dose mass-dependence are lost. The energy could be a great option for dosing, (like it is in radiation therapies by Gy) but it has numerous drawbacks. These are discussed in this paper, trying to unify the dosing of ionizing and non-ionizing radiations.

show abstract

Section: Dosing Methodsmentioning

confidence: 99%

Heating, Efficacy and Dose of Local Hyperthermia

Szász¹,

Szász²

2016

OJBIPHY

Self Cite

View full text Add to dashboard Cite

show abstract

“…(ii) It is in the range of the beta dispersion which is one of the selection factors of oncothermia. (iii) It is low enough to have long wavelength for nearfield use with high penetration into the body when the impedance matching [92] is fixed. (iv) It is high enough to be modulated by time-fractal fluctuations.…”

Section: Methodsmentioning

confidence: 99%

Essentials of Oncothermia

Szász

2013

Conference Papers in Medicine

View full text Add to dashboard Cite

Oncothermia is a method of hyperthermia in oncology, controlling the locally applied deep heat by selectively targeting the cellular membrane of the malignant cells. The selection of the method is based on various biophysical and biochemical achievements. There are various differences between the malignant and healthy cells, which could be used for their selection by heat targeting. The primary selection factor is a different metabolic activity which creates distinguishable environments of the malignant cells. The other factor is the clear difference of dielectric properties of the membrane and near-membrane extracellular electrolytes, marking off the malignancies. There is also a structural factor, which is clear in the different pathological patterns of the malignancy from their healthy counterparts. This last is described by fractal pattern evaluation technique, in which dynamic time-fractal transformation is used for further discernment of the malignancy. My objective is to show a new heating method, which makes oncological hyperthermia controllable and effective.

show abstract

“…Third, heating facilitates the reaction rate of drugs, which potentiates their cytotoxicity. [11,16] This method uses a modulated RF for energy delivery and achieves selective thermal action in nonhomogeneous tissue. [18] SYL contributed equally to this work.…”

Section: Introductionmentioning

confidence: 99%

“…[ 9 ] This advanced treatment produces damage-associated cellular patterns and promotes immunogenic cell death accompanied by the release of damage-associated molecular signal patterns, such as ATP, HMGB1 and hsp70, which have the cytokine-like effects of attracting immune cells. [ 16 , 17 ] The heat-induced increase in the tumor response to radiotherapy is due, at least in part, to an increase in the oxygen supply via increased blood circulation in tumors. The enhanced response of tumors to chemotherapy may be due to various factors.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Modulated electrohyperthermia in locally advanced cervical cancer: Results of an observational study of 95 patients

Lee

Cho

2023

Medicine

View full text Add to dashboard Cite

Most federation of gynecology and obstetrics stage II or higher locally advanced cervical cancer (LACC) patients are treated with concurrent chemoradiotherapy (CCRT); however, recurrence is high, and the prognosis is poor. In this observational retrospective study, data from LACC patients treated with CCRT alone or combined with modulated electrohyperthermia (mEHT) were collected from 2011 to 2018. Ninety-five LACC patients, including 53 (%) treated with CCRT alone and 42 (%) treated with CCRT + mEHT, were enrolled. The complete remission rate significantly increased with CCRT + mEHT compared with CCRT alone among LACC cases with lymph node metastasis (45% vs 71%, P = .0377). Additionally, at the last follow-up point, the no-evidence-of-disease rate significantly improved with CCRT + mEHT compared with CCRT (58% vs 82%, P = .0315). Disease-free survival increased in the CCRT + mEHT group with lymph node metastasis (P = .04). The addition of mEHT to CCRT led to a better therapeutic response in LACC with regional lymph node metastasis without severe complications.Abbreviations: AEs = adverse events, CCRT = concurrent chemoradiotherapy, CR = complete remission, DFS = disease-free survival, HIF-1a = hypoxia-inducible factor-1a, LACC = locally advanced cervical cancer, mEHT = modulated electrohyperthermia, NED = no-evidence-of-disease, OS = overall survival, RF = radio frequency, VEGF = vascular endothelial growth factor.

show abstract

“Quo Vadis” Oncologic Hyperthermia?

Cited by 4 publications

References 51 publications

Heating, Efficacy and Dose of Local Hyperthermia

Heating, Efficacy and Dose of Local Hyperthermia

Essentials of Oncothermia

Modulated electrohyperthermia in locally advanced cervical cancer: Results of an observational study of 95 patients

Contact Info

Product

Resources

About